SEC Filing Summary: Salarius Pharmaceuticals, Inc. (SLRX)
Business Context and Reporting Period
This Form 8-K was filed by Salarius Pharmaceuticals, Inc. on September 9, 2025, reporting events occurring on September 4, 2025. The filing addresses the company's compliance status with The Nasdaq Stock Market LLC listing requirements.
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. The document focuses exclusively on regulatory compliance regarding stock listing standards.
Material Changes and Events
- Regained Bid Price Compliance: On September 4, 2025, the Nasdaq Hearings Panel notified Salarius that it regained compliance with Nasdaq Listing Rule 5550(a)(2) (the "Bid Price Rule"). The company maintained a closing bid price of $1.00 per share or more for at least 10 consecutive business days.
- Mandatory Monitoring: Salarius is subject to a Mandatory Panel Monitor for one year from September 4, 2025. If the company falls out of compliance with the Bid Price Rule during this period, Nasdaq may issue a delisting determination letter.
- Ongoing Equity Standard Noncompliance: The company remains noncompliant with Nasdaq Listing Rule 5550(b)(1) (the "Equity Standard"). Salarius has been granted an extension until October 20, 2025, to achieve compliance with this standard.
Guidance, Outlook, and Risks
The filing contains no financial guidance or management commentary regarding future operations. The primary risk identified is the potential for delisting if the company fails to maintain the $1.00 minimum bid price during the one-year monitoring period or fails to meet the Equity Standard by the October 20, 2025 deadline.
Investor Verification Checklist
- Verify the current stock price to ensure it remains above the $1.00 threshold to avoid immediate delisting risk.
- Confirm the company's progress toward meeting the "Equity Standard" (Rule 5550(b)(1)) before the October 20, 2025 deadline.
- Review the press release filed as Exhibit 99.1 for additional details on the compliance restoration.
- Monitor future 8-K filings for any updates regarding the Equity Standard compliance or further Nasdaq communications.